[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361177-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361177-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","effect-of-the-proteasome-inhibitor-bortezomib-on-histone-modifications-in-human-leukemic-cell-lines","Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines","","Histone-modifying enzymes and histone post-translational modifications (PTMs) regulate chromatin organization and gene activity, and their dysregulation is common in cancer. This study focuses on mixed-lineage leukemia biology and how the proteasome inhibitor bortezomib affects histone PTMs. The analysis compares the MLL cell line MOLM-13 with the chronic myeloid leukemia line K562 and assesses specific H2B and H2A ubiquitination marks plus related transcript effects in MLL-associated pathways.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/effect-of-the-proteasome-inhibitor-bortezomib-on-histone-modifications-in-human-leukemic-cell-lines/361177/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/effect-of-the-proteasome-inhibitor-bortezomib-on-histone-modifications-in-human-leukemic-cell-lines/361177.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological role do histone PTMs play according to the abstract?","Question",{"text":63,"@type":64},"Histone PTMs regulate chromatin structure (euchromatin vs heterochromatin) and gene function (active vs silenced genes). In cancer cells, the levels and activity of histone-modifying enzymes often change, disturbing gene expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cell lines were compared to test the effect of bortezomib?",{"text":68,"@type":64},"The study compared the MLL cell line MOLM-13 and the chronic myeloid leukemic cell line K562 under bortezomib treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What histone modifications were emphasized in the results summary?",{"text":72,"@type":64},"MOLM-13 showed higher levels of H2BK120ub and H3K79me2, while H2AK119ub was also reported at similar levels. After bortezomib treatment, H2BK120ub and H2AK119ub levels decreased insignificantly, along with reduced transcript levels of genes involved in MLL development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361177,1790195678,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nEffect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines  \nHedieh Sattarifard 1, Marvellous Oyeyode 1, Dhanvi Prajapati 1, Angela Duaqui 1, Gurlovleen Kaur 1, Ishdeep Muker 1, Wenxia Luo 2, Ted M. Lakowski 2 and James R. Davie 1, *  \nAcademic Editor: Kwang-Hyun Baek  \nReceived: 4 June 2026  \nRevised: 13 July 2026  \nAccepted: 21 July 2026  \nPublished: 24 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; [sattarih@myumanitoba.ca](sattarih@myumanitoba.ca) (H.S.); [oyeyodem@myumanitoba.ca](oyeyodem@myumanitoba.ca) (M.O.); [duaquia@myumanitoba.ca](duaquia@myumanitoba.ca) (A.D.); [kaurg46@myumanitoba.ca](kaurg46@myumanitoba.ca) (G.K.); [mukeri@myumanitoba.ca](mukeri@myumanitoba.ca) (I.M.)  \n2 Pharmaceutical Analysis Laboratory, College of Pharmacy, University of Manitoba, Winnipeg, MB R3E 0T5, Canada; [luow1@myumanitoba.ca](luow1@myumanitoba.ca) (W.L.); [ted.lakowski@umanitoba.ca](ted.lakowski@umanitoba.ca) (T.M.L.)  \n* [Correspondence: jim.davie@umanitoba.ca](Correspondence: jim.davie@umanitoba.ca)  \nAbstract  \nHistone-modifying enzymes and histone post-translational modifications (PTMs) play key roles in the organization (euchromatin versus heterochromatin) and function (active versus silenced genes) of chromatin. The abundance and activity of these enzymes, along with their associated histone PTMs, are often altered in cancer cells, leading to deregulated gene expression. The expression of the KMT2A-MLLT3 protein, resulting from a chromosomal translocation in mixed-lineage leukemia (MLL), a subtype of acute myeloid leukemia, augments transcription elongation, promoting the expression of HOXA9 and MEIS1, genes that play critical roles in MLL development. Bortezomib, a proteasome inhibitor, has been effective at treating various cancers. In this study, we compared the impact of bortezomib on histone PTMs in the MLL cell line MOLM-13 and the chronic myeloid leukemic (CML) cell line K562 . We report that MOLM-13 had a greater level of histone H2B monoubiquitinated at lysine 120 (H2BK120ub) and histone H3 dimethylated atlysine 79 (H3K79me2) (modifications involved in elongation) and similar levels of histone H2A monoubiquitinated at lysine 119 (H2AK119ub) . Bortezomib treatment resulted insignificant reductions in H2BK120ub and H2AK119ub levels, as well as in transcript levels of genes involved in MLL development.  \nKeywords: proteasome; bortezomib; histone H2B ubiquitinated at lysine 120; histone H2A ubiquitinated at lysine 119  \n1. Introduction  \nAcute myeloid leukemia (AML) is an aggressive blood cancer that affects both adults and children but mainly occurs in pediatric patients. MLL, a subtype of AML, is characterized by a KMT2A rearrangement at 11q23 that can fuse with over 80 partner genes, including but not limited to AFF1/AF4, MLLT10/AF10, MLLT3/AF9, and MLLT1/EN [1] . The KMT2A-MLLT3 fusion protein, resulting from the t(9;11)(p22;q23) translocation, isone of the most common and well-studied fusions in KMT2A-rearranged leukemia. In AML, the KMT2A gene, which codes for an H3K4 lysine methyltransferase, fuses with another protein-coding gene, generating an oncoprotein. In this fusion, KMT2A retains its N-terminus (KMT2AN ), which is placed in frame with the C-terminus of one of several fusion partners, creating an oncogenic chimeric protein. In this translocation, although  \nKMT2A does not contain the H3K4 methylation SET domain, it does contain a CXXC domain that can bind to nonmethylated CpG-rich promoter regions of target genes of KMT2A, like the HOXA9 gene. Upon binding to CpG regions, the fusion protein can recruit DOT1L (KMT4), the Super ","cbCaiaSeXp1Tbguq","https://ap.wps.com/l/cbCaiaSeXp1Tbguq","pdf",3084316,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What biological role do histone PTMs play according to the abstract?\",\"answer\":\"Histone PTMs regulate chromatin structure (euchromatin vs heterochromatin) and gene function (active vs silenced genes). In cancer cells, the levels and activity of histone-modifying enzymes often change, disturbing gene expression.\"},{\"question\":\"Which cell lines were compared to test the effect of bortezomib?\",\"answer\":\"The study compared the MLL cell line MOLM-13 and the chronic myeloid leukemic cell line K562 under bortezomib treatment.\"},{\"question\":\"What histone modifications were emphasized in the results summary?\",\"answer\":\"MOLM-13 showed higher levels of H2BK120ub and H3K79me2, while H2AK119ub was also reported at similar levels. After bortezomib treatment, H2BK120ub and H2AK119ub levels decreased insignificantly, along with reduced transcript levels of genes involved in MLL development.\"}]","Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines | PDF",1790143412,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f88e93a112c32a1a6e276c498300db97.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a17593289c1004f293cbc0bcfecfcee.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87b8ea46a7700f0077b9675ebd8f0ba7.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc10095eb7fc4fdb5f3bed55339061c.webp",980,1385]